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Background: If national peak Human Immunodeficiency Virus (HIV) prevalence is positively associated with the
prevalence of other sexually transmitted infections (STIs) from before or early on in the HIV epidemics this would
suggest common underlying drivers.
Methods: Pearson’s correlations were calculated between the prevalence of seven STIs at a country-level:
chlamydia, gonorrhoea, trichomoniasis, syphilis, bacterial vaginosis, herpes simplex virus-2 (HSV-2) and HIV.
Results: The prevalence of all the STIs was highest in the sub-Saharan African region excluding chlamydia.
The prevalence of all seven STIs were positively correlated excluding chlamydia. The correlations were
strongest for HIV-HSV-2 (r = 0.85, P < 0.0001) and HSV-2-trichomoniasis (r = 0.82, P < 0.0001).
Conclusion: Our results of a generally positive association between the prevalences of a range of STIs
suggests that higher prevalences were driven by common underlying determinants. We review different
types of evidence which suggest that differential sexual connectivity is a plausible common determinant.
Background
The spread of HIV around the world has been far from
uniform. Only 20 countries have had generalized HIV
epidemics (peak HIV prevalence greater than 5%) [1]. In
these countries HIV prevalence typically increased from
under 1% to over 10% in 10 years [2, 3]. Another 30
countries had peak HIV prevalence between 1 and 5%
and in the remaining countries, HIV peaked below 1%
[1]. Some authors have argued that this pattern of spread
can be most parsimoniously explained by affected popu-
lations having more connected sexual networks [4–6].
Others have however argued that a range of other fac-
tors such as differences in the prevalence of circumci-
sion, herpes simplex virus-2 (HSV-2) and other (sexually
transmitted infections) STIs are responsible [7–10].
In this paper, we explore this issue from a novel angle
by testing if there is an association between national
peak HIV prevalence and the prevalence of other STIs
from before or early on in the HIV epidemics. The ra-
tionale we use is that if peak HIV prevalence is strongly
associated with other viral, bacterial and eukaryotic STIs
then this suggests that a common factor underpins this.
STIs like syphilis are curable and thus differences in
syphilis prevalence may be due to differences in treat-
ment efficacy. HSV-2, however, is incurable and thus
treatment efficacy cannot explain differential HSV-2
spread (Fig. 1). If HSV-2 from early on in the HIV era is
found to predict subsequent peak HIV prevalence this
would suggest that the common risk factor is not STI
treatment efficacy.
Methods
Through preferentially affecting those at the highest risk
parts of sexual networks the AIDS epidemics have been
shown to reduce network connectivity and thereby STI
transmission [11–13]. This effect has been noted in both
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men who have sex with men in the United States and in
general populations in Africa [11, 12, 14]. To avoid the
misclassification bias this could introduce, we used na-
tional STI prevalence figures from as early on in the
HIV epidemics as were available in sufficient breadth
and quality. As described in more detail below, these
were generally from the year 1990 or before. We chose
to relate these STI prevalence data to peak HIV preva-
lence rather than HIV prevalence estimates from the
same time as the STI prevalence data as this has been
shown to avoid the HIV introduction bias [2].
Chlamydia, gonorrhoea, syphilis, trichomoniasis
Data for the prevalence estimates for gonorrhea, chla-
mydia, trichomoniasis and syphilis in the year 1990 were
taken from the Global Burden of Diseases Study [15].
For this study the incidence and prevalence of each of
these STIs were estimated by a literature and database
review conducted by the World Health Organization.
Prevalence refers to the percent of women 10 years of
age or older who are infected with each STI at the be-
ginning of 1990.The figures are age-standardized. The
prevalence data used to model infection came from a
comprehensive literature review conducted by a panel of
STI epidemiology experts at the World Health
Organization. Only studies sampling low risk subjects
(primarily antenatal populations) were included. The
data used spanned the years 1981 to 2010. The preva-
lence data and gaps therein were modelled separately
using DisMod 3, a meta-regression tool that forces all
parameters (prevalence, remission etc.) into consistency
with one another [16].
HSV-2
The HSV-2 prevalence data we used (prevalence in
40–44 year old women) was extracted from a previ-
ously published study that assessed the association
between HSV-2 prevalence in 40–44 year old women
and peak HIV prevalence [17]. The comparative HSV-
2 prevalence data for this study was taken from two
systematic reviews of global HSV-2 incidence and
prevalence [18, 19]. These reviews were conducted in
2002 and 2005 and used data published between 1986
and 2003. Only studies that reported age and gender
specific HSV-2 prevalence (assessed by type specific
serology) and measuring this in population-based
samples were included.
Fig. 1 Conceptual framework to understand the relationship between proximate and distant determinants of HIV prevalence. Of note STI
treatment efficacy can have an impact on the prevalence of all STIs except HSV-2 which is incurable (Dotted red arrows)
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Bacterial vaginosis (BV)
BV prevalence estimates were extracted from a system-
atic review of the global epidemiology of BV [20]. This
study summarized BV prevalence from studies spanning
the period 1984 to 2012. Only studies that used repre-
sentative population samples or low risk antenatal sam-
ples were included. The Nugent scoring system has been
recommended as the gold standard for studies compar-
ing the prevalence of BV [21]. We therefore only in-
cluded studies where the diagnosis of BV was based on
the Nugent system. BV is generally regarded as a sexu-
ally associated disease rather than an STI but in the in-
terests of succinctness we describe it as an STI.
National peak HIV prevalence
National HIV prevalence estimates were taken from 1990
to 2009 in the Global Health Observatory Data Repository
of the World Health Organization (http://apps.who.int/
gho/data/node.main.622). These estimates are based on
population-based testing, antenatal clinical surveillance,
and epidemic models [22]. We used these data to calculate
the peak HIV prevalence variable as the highest HIV
prevalence (in 15- to 49-year-olds) attained in each coun-
try obtained between the years 1990 to 2009 (median year,
1998; interquartile range, 1996–2005) [1, 2].
Ethical statement
The research involved secondary data analysis of STI
prevalence estimates. No specific ethics committee ap-
proval was therefore necessary for this study.
Statistical analysis
Pearson’s correlation (with Bonferroni corrections) was
used to evaluate the relationship between each of the STIs.
HIV prevalences were natural log- and TV prevalences
cubic-transformed to create more normal distributions for
regression analyses. All analyses were performed in
STATA 13.0 (StataCorp LP, College Station, TX).
Results
There were large variations in the national prevalences of
HIV (median 0.4%, IQR 0.1–1.6), HSV-2 (median 27.4%,
IQR 17.5–50.9), chlamydia (median 25.0/1000, IQR 21.6–
42.1), gonorrhoea (median 9/1000, IQR 7.4–10.1), syphilis
(median 0.1/1000, IQR 0.0–0.2), trichomoniasis (median
22.9/1000, IQR 18.8–26.4) and BV (median 18.3%, IQR
13.7–29.2; Table 1).
The prevalence of all seven STIs were positively corre-
lated excluding chlamydia which was negatively correlated
with the other STIs (Table 2a, Fig. 2). The correlations
were strongest for HIV-HSV-2 (r = 0.85, P < 0.0001) and
HSV-2-trichomoniasis (r = 0.82, P < 0.0001). The preva-
lence of all the STIs was highest in the sub-Saharan
African region (Table 1, Fig. 2) excluding chlamydia. The
chlamydia prevalences for sub-Saharan African countries
clustered tightly around 2000/100000 population. The
positive correlations were largely driven by higher STI
prevalences in sub Saharan Africa. Repeating the correla-
tions limited to non-sub Saharan Africa reduced the
strength of the associations (Table 2b).
Discussion
We found a strong positive association between 6 of the 7
STIs evaluated. Countries with high peak HIV prevalences
had high prevalences of other STIs –excluding chlamydia-
preceding or early in the HIV epidemics. This pattern
strongly suggests that a common factor(s) underpinned
the more extensive spread of STIs in these populations.
To some extent these associations were driven by the
higher STI prevalences in sub-Saharan Africa. The clear
exception was chlamydia where the prevalence estimates
for sub-Saharan Africa clustered tightly in the lower tertile
of prevalence estimates. There are a number of possible
explanations for the differences in distribution between
chlamydia and other STIs. The fact that the prevalence es-
timates of chlamydia for African countries clustered
tightly around a single value may be due to the low num-
ber of data points available for this region for this time
point – 21 data points for the period 1981 to 2010 [15]. It
was not specified how many of these data points were
used to provide the estimates for the 1990 estimates. It is
noteworthy that the WHO in its first global prevalence of
STIs report in 1995 estimated the prevalence of chlamydia
in sub Saharan Africa in 15–49 year old women and men
was 7.1% and 4.8%, respectively – considerably higher
than all other world regions [23, 24]. By the 2000 and
2005 global reports, the estimated prevalence of chlamydia
in sub-Saharan Africa was lower than in a number of
other regions. A combination of chlamydia’s long duration
of (frequently asymptomatic) infection which enables it to
spread easily in sexual networks and a degree of immunity
following natural clearance of the infection may result in a
Table 1 Median (interquartile range) prevalence of seven
sexually transmitted infections in all countries and those in sub
Saharan Africa
Na All countries Na Sub Saharan Africa
HIV 170 0.4 (0.1–1.6) 51 3.5 (1–7.9)
HSV-2 64 27.2 (17.5–50.9) 20 64 (50.9–79.5)
Chlamydia 166 2.5 (2.2–3.4) 51 2.2(2.1–2.2)
Gonorrhea 166 0.9 (0.8–1.0) 51 1.1 (1.0–1.2)
Syphilis 166 0.01 (0.009–0.02) 51 0.02 (0.02–0.02)
BV 42 18.3 (13.7–29.2) 13 30.3 (25.0–38.1)
Trichomoniasis 166 2.3 (2.0–3.9) 51 4.1(4.0–4.2)
a Number of countries with data for those with peak HIV prevalence
data available
Abbreviations: HIV human immunodeficiency virus, HSV-2 herpes simplex virus-2,
BV bacterial vaginosis
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higher prevalence of chlamydia in lower risk sexual net-
works (and lower prevalence of other STIs) than higher
risk networks [25, 26].
Limitations
The validity of our study depends on the accuracy of the
individual STI prevalence estimates. Whilst the HIV
estimates are based on high quality data (frequent nation-
ally representative samples) the HSV-2 and BV estimates
are based on intermediate quality data and the bacterial/
protozoan STI estimates on modelled data of, at times, a
low number of data points. Our results are however
largely concordant with studies using different data
sources. One study that only used syphilis prevalence data
Table 2 Pair-wise correlation between the prevalence of 7 sexually transmitted infections in all countries (a) and excluding countries
from sub Saharan Africa (b) [Data from various sources]




Chlamydia −.11 −.23 –
Gonorrhoea .44*** .58*** −.69*** –
Syphilis .50*** .67*** −.03 .15 –
Trichomoniasis .75*** .83*** −.41*** .75*** .56*** –




Chlamydia .34** .27 –
Gonorrhoea −.25 −.18 −.62*** –
Syphilis .07 −.02 .37*** −.60*** –
Trichomoniasis .10 .12 −.13 .48*** −.23 –
BV .29 .29 −.05 .05 .26 .15
P-Value: * < .05, ** < .005, *** < .0005 (Including Bonferroni corrections)
Abbreviations: HIV human immunodeficiency virus, HSV-2 herpes simplex virus-2, BV bacterial vaginosis
a b c
d e f
Fig. 2 Association between national peak HIV prevalence and chlamydia (a), gonorrhea (b), syphilis (c), T. vaginalis (d), bacterial vaginosis (e), HSV-2
prevalence (f). (Blue dots - countries in sub Saharan Africa, red dots- other countries, data sources detailed in text)
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from antenatal populations for example found a similarly
strong association between syphilis prevalence in the
1990s and peak HIV prevalence [27]. With the exception
of chlamydia noted above, the WHO global STI epidemi-
ology reports from 1995, 2001, 2005 and 2012 [28–31] all
noted higher prevalences of the bacterial/protozoan STIs
in the sub Saharan African region.
There is a paucity of nationally representative STI
prevalence data preceding the HIV era. Arguably the best
quality data comes from antenatal syphilis prevalence
(ASP) surveys whose prevalence estimates have been
shown to reasonably approximate that of the population
at large and where testing has been widespread for over
50 years [32]. A study that used antenatal syphilis pre-
valence to describe the global epidemiology of syphilis
over the past century found that countries in sub Saharan
Africa had a less marked decline in ASP following the
introduction of penicillin and that ASP settled at a consid-
erably higher plateau here than elsewhere, including other
low and middle income countries [33]. ASP in Southern
and Eastern African countries from the pre-AIDS period
plateaued at a median 10% until the HIV epidemic; inter-
quartile range, 6.5–11.5% [33, 34]. No correlation was
found between syphilis screening and treatment efficacy
and ASP [33]. A review of syphilis epidemiology based on
case reporting conducted by the WHO for the years 1945
to 1958, also found that the incidence of syphilis was high-
est in sub Saharan Africa [35].
Further support for the clustering of STIs at national/
regional level comes from epidemiological studies of
other STIs, such as lymphogranuloma venereum, dono-
vanosis, human papilloma virus and chancroid, from the
pre/early HIV period which found the prevalence in
sub-Saharan Africa to be as high or higher than other
world regions [36–38].
Clustering of STIs at world regional and sub-national
levels
The best quality evidence for the clustering of STIs,
however, comes from sub national populations. Studies
from Ethiopia, Kenya, South Africa, Uganda, the United
Kingdom and the United States have found that ethnic
groups with high HIV prevalences had higher preva-
lences of other STIs in the pre- or early-HIV period [5,
17, 20, 39, 40]. In the USA, for example, data from
nationally representative samples established that the
prevalences of HSV-2, chlamydia, gonorrhea, syphilis,
and trichomoniasis were 3.2, 6.5, 16.2, 4.9 higher in non
Hispanic blacks than non Hispanic whites [5]. Studies
based on antenatal syphilis prevalence, serological
testing of military recruits and case based surveillance
demonstrated that this relative difference in syphilis
prevalence has been present for at least 70 years [33,
41–44]. Likewise, HSV-2 prevalence estimates from
nationally representative surveys found considerably
higher prevalences in non Hispanic blacks than non His-
panic whites in the United States since the first survey
in 1976 [45, 46]. Similarly, data from antenatal surveys
and case surveillance in the 1930s to 1950s in South
Africa showed that ethnic groups that went on to have
high peak HIV prevalence had approximately 10 times
higher syphilis prevalence from the 1930s until contem-
porary times than ethnic groups that had low peak HIV
prevalence [33, 47, 48]. Rates of HSV-2/other STIs by
ethnic group in South Africa, Uganda and Kenya
followed a similar pattern [17, 49–51].
STIs have also been found to cluster at the level of
world regions. Using partitioning according to medoids,
one study found that there was sufficient clustering of 6
STIs to support classifying WHO world regions accord-
ing to high, medium and low prevalence regions [26].
How can we explain the clustering of STIs?
A striking feature of the clustering of STIs is that it in-
cludes a wide range of viral, prokaryotic, and eukaryotic
organisms. This makes it less likely that differential gen-
etic susceptibility is responsible for these different STI
rates [5]. Differential STI treatment efficacy has long
been argued to play a dominant role [52]. Whilst STI
treatment efficacy is of crucial importance, differential
access to treatment cannot explain the differential
spread of incurable STIs such as HSV-2 [17]. Our find-
ing that HSV-2 is predictive of peak HIV prevalence thus
means that treatment efficacy cannot by itself explain
the clustering of STIs. Furthermore, studies that have
examined this in detail have found little or no associ-
ation between treatment efficacy and STI prevalence [33,
53]. Likewise, although condom usage and circumcision
are protective for the acquisition of STIs, there is little
evidence that they explain the higher prevalence of STIs in
sub-Saharan Africa [54, 55]. In South Africa for example
where HIV prevalence varies by 40-fold between ethnic
groups, the high prevalence groups have a three-fold higher
circumcision and higher reported condom usage than the
low HIV prevalence groups [56]. Whilst HIV was consid-
ered by many to be a disease of poverty, studies using na-
tionally representative HIV-serolinked samples from 19
countries have demonstrated that HIV prevalence generally
increases monotonically with wealth [57].
An emerging body of evidence suggests that combina-
tions of the following factors determine STI prevalence:
differential sexual network connectivity (determined by
factors such as partner number, timing and concurrency)
[5, 58, 59], factors that enhance the probability of trans-
mission per contact (such as age gap and absence of cir-
cumcision or condom usage) [60, 61] and STI treatment
efficacy. According to this conception, each population
will have its own combination of these factors and this
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specific network transmission index (NTI) will play a large
role in determining the prevalence of STIs [61]. Although
there is still considerable debate on the topic, the network
connectivity component of NTI has been shown to be a
parsimonious explanation for both inter- and intra-national
variations in STI prevalence [58, 59, 61, 62]. Markers of
network connectivity, such as sexual partner concurrency,
have been found to be positively correlated with the preva-
lences of HIV [6], HSV-2 [63], BV [64], syphilis [65] and
trichomoniasis [61]. Furthermore, historical studies from
South Africa suggest that differential network connectivity
by ethnic group could explain the differences in syphilis
prevalence since the 1930s [33, 66, 67].
Conclusion
The finding that differences in STI prevalence by popu-
lation have persisted for over 50 years requires further
study but suggests that radical STI prevention will re-
quire strategies that target the underlying determinants
of NTI. Uganda’s ‘Zero Grazing’ campaign, where indi-
viduals were encouraged to have only one sexual partner
at a time, is one example of an intervention that made
progress in this regard [68].
Our results of a positive association between a range
of STIs provide further impetus to efforts that more ac-
curately delineate and target the common underlying de-
terminants of elevated STI prevalence.
Acknowledgements
The authors would like to thank the Global Burden of Diseases Study and
the Institute for Health Metrics and Evaluation for kindly sharing the STI
prevalence data from 1990.
Funding
No funding was received for this study.
Availability of data and materials
All data is publically available from sources specified in the text, except the
data from the Global burden of Diseases Study which can be obtained from:
http://www.healthdata.org/gbd/data.
Author’s contributions
CK was responsible for all aspects of the study.
Ethics approval and consent to participate
The research involved secondary data analysis of STI prevalence estimates.




The author declares he has no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Received: 30 May 2017 Accepted: 4 October 2017
References
1. Kenyon C, Buyze J. Should the threshold for generalized HIV epidemics be
1% or 5%? Int J STDs & AIDS. 2014;25:898.
2. Kenyon C, Colebunders R, Voeten H, Lurie M. Peak HIV prevalence: a useful
outcome variable for ecological studies. Int J Infect Dis. 2013;17(5):e286–8.
3. HIV/AIDS. JUNPo, Organization WH: AIDS epidemic update, 2006: World
Health Organization; 2007.
4. Goodreau SM, Cassels S, Kasprzyk D, Montano DE, Greek A, Morris M.
Concurrent partnerships, acute infection and HIV epidemic dynamics
among young adults in Zimbabwe. AIDS Behav. 2012;16(2):312–22.
5. Morris M, Kurth AE, Hamilton DT, Moody J, Wakefield S. Concurrent
partnerships and HIV prevalence disparities by race: linking science and
public health practice. Am J Public Health. 2009;99(6):1023–31.
6. Kenyon CR, Tsoumanis A, Schwartz IS, et al. Partner concurrency and HIV
infection risk in South Africa. Int J Infect Dis 2016;45:81–7.
7. Drain PK, Halperin DT, Hughes JP, Klausner JD, Bailey RC. Male circumcision,
religion, and infectious diseases: an ecologic analysis of 118 developing
countries. BMC Infect Dis. 2006;6:172.
8. Auvert B, Buve A, Ferry B, Carael M, Morison L, Lagarde E, Robinson NJ,
Kahindo M, Chege J, Rutenberg N, et al. Ecological and individual level
analysis of risk factors for HIV infection in four urban populations in
sub-Saharan Africa with different levels of HIV infection. AIDS. 2001;
15(Suppl 4):S15–30.
9. Auvert B, Buve A, Lagarde E, Kahindo M, Chege J, Rutenberg N, Musonda R,
Laourou M, Akam E, Weiss H. Male circumcision and HIV infection in four
cities in sub-Saharan Africa. AIDS. 2001;15:S31.
10. Buve A. The HIV epidemics in sub-Saharan Africa: why so severe? Why so
heterogenous? An epidemiological perspective. The HIV/AIDS Epidemic in
Sub-Saharan Africa Historical Perspective. 2006:41–55.
11. Chesson HW, Dee TS, Aral SO. AIDS mortality may have contributed to the
decline in syphilis rates in the United States in the 1990s. Sex Transm Dis.
2003;30(5):419–24.
12. Kenyon CR, Schwartz I, Buyze J. Did AIDS mortality decrease the number of
lifetime sexual partners in Kenya: an ecological analysis? Epidemiol Infect.
2016;144(3):556–9.
13. Johnson LF, Dorrington RE, Bradshaw D, Coetzee DJ. The effect of
syndromic management interventions on the prevalence of sexually
transmitted infections in South Africa. Sex Reprod Healthc. 2011;2(1):13–20.
14. Kenyon CR, Osbak K, Buyze J, Chico RM. The changing relationship between
bacterial STIs and HIV prevalence in South Africa - an ecological study. Int J
STD AIDS. 2015;26(8):556-64. doi:10.1177/0956462414546392.
15. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J,
Adair T, Aggarwal R, Ahn SY, et al. Global and regional mortality from 235
causes of death for 20 age groups in 1990 and 2010: a systematic analysis for
the global burden of disease study 2010. Lancet. 2012;380(9859):2095–128.
16. Institute for Health Metrics and Evaluation. Global burden of disease
study 2010 (GBD 2010). Sexually transmitted infection prevalence 1990–
2010. Seattle; 2011.
17. Kenyon C, Colebunders R, Hens N. Determinants of generalized herpes
simplex virus-2 epidemics: the role of sexual partner concurrency. Int J STD
AIDS. 2013;24(5):375–82.
18. Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence
and incidence of herpes simplex virus type 2 infection. Bull World Health
Organ. 2008;86(10):805–812, A.
19. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes
simplex virus types 2 and 1: a global review. J Infect Dis. 2002;
186(Supplement 1):S3–S28.
20. Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial
vaginosis: a systematic review. Am J Obstet Gynecol. 2013;209(6):505–23.
21. Marrazzo JM, Martin DH, Watts DH, Schulte J, Sobel JD, Hillier SL, Deal C,
Fredricks DN. Bacterial Vaginosis: identifying research gaps proceedings of a
workshop sponsored by DHHS/NIH/NIAID November 19-20, 2008. Sex
Transm Dis. 2010;37(12):732.
22. UNAIDS. Methodology – understanding the HIV estimates. Geneva:
UNAIDS; 2014.
23. Gerbase A, Rowley J, Heymann D, Berkley S, Piot P. Global prevalence
and incidence estimates of selected curable STDs. Sex Transm Infect.
1998;74(1):12.
Kenyon BMC Infectious Diseases  (2017) 17:682 Page 6 of 7
24. World Health Organization WHOOoI. Sexually transmitted infections increasing
– 250 million new infections annually. WHO Feature. 1990;152:1–6.
25. Wylie JL, Shaw S, DeRubeis E, Jolly A. A network view of the transmission of
sexually transmitted infections in Manitoba, Canada. Sex Transm Infect.
2010;86(Suppl 3):iii10–6.
26. Kenyon C, Colebunders R, Buyze J. Classification of incidence and
prevalence of certain sexually transmitted infections by world regions. Int J
of Infec Dis. 2014;18:73–80.
27. Osbak KK, Rowley JT, Kassebaum NJ, Kenyon CR. The prevalence of syphilis
from the early HIV period is correlated with peak HIV prevalence at a
country level. Sex Transm Dis. 2016;43(4):255–7.
28. World Health Organization. Global prevalence and incidence of selected
curable sexually transmitted diseases: overview and estimates. Geneva:
World Health Organization; 1995.
29. World Health Organization. Global prevalence and incidence of selected
curable sexually transmitted diseases: overview and estimates. Geneva:
World Health Organization; 2001.
30. World Health Organization. Prevalence and incidence of selected sexually
transmitted infections, Chlamydia trachomatis, Neisseria gonorrhoeae,
syphilis, and Trichomonas vaginalis: methods and results used by the WHO
to generate 2005 estimates. Geneva: World Health Organization; 2011.
31. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N,
Stevens G, Gottlieb S, Kiarie J, Temmerman M. Global estimates of the
prevalence and incidence of four curable sexually transmitted infections in
2012 based on systematic review and global reporting. PLoS One. 2015;
10(12):e0143304.
32. Cal Ham D, Lin C, Newman L, Saman Wijesooriya N, Kamb M.
Improving global estimates of syphilis in pregnancy by diagnostic test
type: a systematic review and meta-analysis. Int J Gynecol Obstet. 2015;
130(Suppl 1):S10–24.
33. Kenyon CR, Osbak K, Tsoumanis A. The global epidemiology of syphilis in
the past century - a systematic review based on antenatal syphilis
prevalence. PLoS Negl Trop Dis. 2016;10(5):e0004711.
34. Kenyon CR, Osbak K, Chico RM. What underpins the decline in syphilis in
southern and eastern Africa? An exploratory ecological analysis. Int J Infect
Dis. 2014;29:54–61.
35. Guthe T. The treponematoses as a world problem. Brit J Venereal Dis.
1960;36(2):67.
36. Laga M, Nzila N, Goeman J. The interrelationship of sexually transmitted
diseases and HIV infection: implications for the control of both epidemics in
Africa. AIDS. 1991;5:S55.
37. Cunningham A, Mindel A, Dwyer D. Global epidemiology of sexually
transmitted diseases. In: Stanberry L, Bernstein D, editors. Sex transmitted
diseases. San Diego: Academic Press; 2000.
38. Bruni L, Diaz M, Castellsagué M, Ferrer E, Bosch FX, de Sanjosé S. Cervical
human papillomavirus prevalence in 5 continents: meta-analysis of 1 million
women with normal cytological findings. J Infect Dis. 2010;202(12):1789–99.
39. Kenyon C, Osbak K, Buyze J. The prevalence of HIV by ethnic group is
correlated with HSV-2 and syphilis prevalence in Kenya, South Africa, the
United Kingdom and the United States. Interdiscipl Perspect Infect Dis.
2014;Article ID:284317.
40. Kenyon CR, Tsoumanis A, Schwartz IS. HIV prevalence correlates with high-
risk sexual behavior in Ethiopia’s regions. PLoS One. 2015;10(10):e0140835.
41. Leiby GM, Turner TB, et al. Studies on syphilis in the eastern Health District
of Baltimore city; syphilis among parturient women as an index of the trend
of syphilis in the community. Am J Hyg. 1947;46(2):260–7.
42. Gordon T, Devine B. Findings on the serologic test for syphilis in adults,
United States 1960-1962. Vital Health Stat 11. 1965;11:1–31.
43. Nakashima AK, Rolfs RT, Flock ML, Kilmarx P, Greenspan JR. Epidemiology of
syphilis in the United States, 1941-1993. Sex Transm Dis. 1996;23(1):16–23.
44. Vonderlehr R, Usilton LJ. Syphilis among men of draft age in the United
States: an analysis of 1,895,778 serologic reports of men aged 21-35 who
were examined under the selective training and service act of 1940. J Am
Med Assoc. 1942;120(17):1369–72.
45. Fleming DT, McQuillan GM, Johnson RE, Nahmias AJ, Aral SO, Lee FK, St
Louis ME. Herpes simplex virus type 2 in the United States, 1976 to 1994. N
Engl J Med. 1997;337(16):1105–11.
46. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, Berman
SM, Markowitz LE. Trends in herpes simplex virus type 1 and type 2
seroprevalence in the United States. JAMA. 2006;296(8):964–73.
47. O'Malley CK. Syphilis in South Africa. S Afr Med J. 1940;14(23):459–62.
48. Kark SL. The social pathology of syphilis in Africans 1949. Int J Epidemiol.
2003;32(2):181–6.
49. South African Department of Health. The 2012 National Antenatal Sentinel
HIV & Herpes Simplex Type-2 prevalence survey. In: National Department of
health Pretoria; 2013.
50. Central Bureau of Statistics (CBS) [Kenya] Ministry of Health (MOH) [Kenya]
and ORC Macro: Kenya demographic and health survey 2003. In. Calverton,
Maryland: CBS, MOH, and ORC; 2004.
51. Hackett CL. Incidence of yaws and of venereal diseases in Lango (Uganda).
Br Med J. 1947;1(4489):88–90.
52. Aral SO, Over M, Manhart L, Holmes KK. Sexually transmitted infections. In:
Jamison DT, Mosley WH, editors. Disease control priorities in developing
countries: health policy responses to epidemiological change. Volume 2.
Washington (DC): World Bank; 2006. p. 653–89.
53. Kenyon CR, Vu L, Menten J, Maughan-Brown B. Male circumcision and
sexual risk behaviors may contribute to considerable ethnic disparities in
HIV prevalence in Kenya: an ecological analysis. PLoS One. 2014;9(8):
e106230.
54. Drain PK, Smith JS, Hughes JP, Halperin DT, Holmes KK. Correlates of
national HIV seroprevalence: an ecologic analysis of 122 developing
countries. J Acquir Immune Defic Syndr. 2004;35(4):407–20.
55. Kenyon C, Buyze J. Correlation between National Peak HIV prevalence and
concurrency, STI treatment capability, condom use and circumcision: an
ecological study. World J AIDS. 2014;4(2):249–57.
56. Kenyon C. Association of HIV prevalence and concurrency of sexual
partnerships in South Africa’s language groups: an ecological analysis.
Southern African J HIV Med. 2013;14(1):25–8.
57. Vinod M, Medley A, Hong R, Gu Y, Robey B. Levels and Spread of HIV
Seroprevalence and Associated Factors: Evidence from National Household
Surveys. DHS Comparative Reports No. 22. Calverton: Macro International
Inc.; 2009.
58. Johnson LF, Dorrington RE, Bradshaw D, Pillay-Van Wyk V, Rehle TM. Sexual
behaviour patterns in South Africa and their association with the spread of
HIV: insights from a mathematical model. Demogr Res. 2009;21:289.
59. Kenyon C, Colebunders R. Strong association between point-concurrency
and national peak HIV prevalence. Int J Infect Dis. 2012;16(11):e826–7.
60. Barnighausen T, Tanser F. Rethinking the role of the local community in HIV
epidemic spread in sub-Saharan Africa: a proximate-determinants approach.
HIV Ther. 2009;3(5):435–45.
61. Kenyon CR, Buyze J, Klebanoff M, Brotman RM. Incident Trichomonas
vaginalis is associated with partnership concurrency: a longitudinal cohort
study. Sex Transm Dis. 2017;
62. Aral SO. Partner concurrency and the STD/HIV epidemic. Curr Infect Dis Rep.
2010;12(2):134–9.
63. Kenyon C, Colebunders R, Buve A, Hens N. Partner-concurrency associated
with herpes simplex virus 2 infection in young South Africans. Int J STD
AIDS. 2013;24:804–12.
64. Kenyon CR, Colebunders R. Strong association between the prevalence of
bacterial vaginosis and male point-concurrency. Eur J Obstet Gynecol
Reprod Biol. 2014;172:93–6.
65. Kenyon CR, Osbak K. The prevalence of syphilis is associated with the
prevalence of male point-concurrency: an ecological analysis. World J AIDS.
2015;5(2):131–9.
66. Kenyon C, Zondo S. Why do some south African ethnic groups have very
high HIV rates and others not? African J AIDS Res. 2011;10(1):51–62.
67. Delius P, Glaser C. The myths of polygamy: a history of extra-marital and
multi-partnership sex in South Africa. South African Hist J. 2004;50(1):84–114.
68. Kirby D. Changes in sexual behaviour leading to the decline in the
prevalence of HIV in Uganda: confirmation from multiple sources of
evidence. Sex Transm Dis. 2008;84(Suppl 2):ii35–41.
Kenyon BMC Infectious Diseases  (2017) 17:682 Page 7 of 7
